Evidence map›Paper›PMID 39920136›Full record

ArticleCell death & disease2025

Regulation of NK cell development, maturation, and antitumor responses by the nuclear receptor NR2F6.

Johannes Woelk, Florian Hornsteiner, Stephanie Aschauer-Wallner, Patrizia Stoitzner, Gottfried Baier, Natascha Hermann-Kleiter

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Loss of NR2F6 Protects from Salmonella Typhimurium Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Johannes WoelkInstitute of Cell Genetics, Department for Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0003-3535-5576
Florian HornsteinerDepartment of Dermatology, Venereology & Allergology, Medical University of Innsbruck, Innsbruck, Austria.
Stephanie Aschauer-WallnerLaboratory of Tumor Immunology, Tyrolean Cancer Institute & Internal Medicine V, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Patrizia StoitznerDepartment of Dermatology, Venereology & Allergology, Medical University of Innsbruck, Innsbruck, Austria.
Gottfried BaierInstitute of Cell Genetics, Department for Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-2085-8325
Natascha Hermann-KleiterInstitute of Cell Genetics, Department for Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria. natascha.kleiter@i-med.ac.at.ORCID 0000-0003-4389-9813

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) DOIs10.55776/P33855EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ERC_ADG #786462Österreichischen Akademie der Wissenschaften (Austrian Academy of Sciences) OAW DOC/26015
6 · The paper itself

Abstract

Natural killer (NK) cell development and functionality rely on precise regulation by specific transcription factors (TFs). Our study demonstrates that the nuclear orphan receptor NR2F6 represses the expression of the activating receptor NKp46, an established key player in NK cell-mediated cytotoxicity during infection and tumor rejection. Despite normal NK cell development in the bone marrow, germline Nr2f6-deficient mice exhibit impaired terminal maturation of NK cells in the periphery. Short-term NK cell responses to lipopolysaccharide (LPS) activation, independent of NKp46, are subsequently reduced in Nr2f6-deficient mice. Conventional type 1 dendritic cells (cDC1) and macrophage populations are decreased in spleens of Nr2f6-deficient mice, subsequently, IL-15-dependent NK cell priming is limited. Administration of exogenous IL-15 in vitro and as IL-15 complex in vivo can compensate for these deficits, promoting terminal maturation of NK cells in Nr2f6-deficient mice. Subsequent transcriptome analysis reveals significant changes in gene expression profiles of NK cells from IL-15 complex treated Nr2f6-deficient mice, with notable alterations in essential NK genes such as Klrg1, Prdm1, Stat5a, Zeb2, and Prf1. Consequently, Nr2f6-deficient IL-15 complex-treated NK cells raise enhanced effector responses of IFNγ, Perforin, and Granzyme B upon ex vivo activation. Of importance, Nr2f6-deficient mice are protected against MHC-I negative B16-F10 melanoma lung metastasis formation, especially with IL-15 complex treatment, indicating the potential of NR2F6 to affect NKp46-dependent NK cell-mediated tumor surveillance. The therapeutic targeting of NR2F6 may be a promising strategy for boosting NKp46-dependent NK-cell-mediated tumor surveillance and metastasis.

Indexed as

COUP Transcription FactorsKiller Cells, NaturalAnimalsAntigens, LyCell DifferentiationDendritic CellsInterleukin-15LipopolysaccharidesMiceMice, Inbred C57BLMice, KnockoutNatural Cytotoxicity Triggering Receptor 1Repressor ProteinsAntigens, LyCOUP Transcription FactorsInterleukin-15LipopolysaccharidesNatural Cytotoxicity Triggering Receptor 1Ncr1 protein, mouseNr2f6 protein, mouseRepressor Proteins

Identifiers

PMID39920136
PMCPMC11806049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.